Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney

Modern Pathology

Volumn 25, Issue 1, 2012, Pages 100-111

  Martignoni, Guido ^a   Bonetti, Franco ^a   Chilosi, Marco ^a   Brunelli, Matteo ^a   Segala, Diego ^a   Amin, Mahul B ^b   Argani, Pedram ^c   Eble, John N ^d   Gobbo, Stefano ^a   Pea, Maurizio ^e  

^a UNIVERSITY OF VERONA   (Italy)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e Ospedale Orlandi   (Italy)

Author keywords

angiomyolipoma; cathepsin K; epithelioid angiomyolipoma; PEC; PEComa; tuberous sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CATHEPSIN K; CD68 ANTIGEN; MELAN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR;

ANGIOMYOLIPOMA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIOID CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY INTERSTITIUM; KIDNEY TUMOR; LEIOMYOMA; LIPOMA; LYMPHANGIOLEIOMYOMATOSIS; MOLECULAR PATHOLOGY; ONCOCYTOMA; PERIVASCULAR EPITHELIOID CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ADENOMA, OXYPHILIC; ANGIOMYOLIPOMA; CASE-CONTROL STUDIES; CATHEPSIN K; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; KIDNEY NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; PERIVASCULAR EPITHELIOID CELL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855359368     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.136     Document Type: Article

References (40)

1. Martignoni G, Pea M, Reghellin D, et al. Perivascular epithelioid cell tumor (PEComa) in the genitourinary tract. Adv Anat Pathol 2007;14:36-41. (Pubitemid 46052180)
2. Martignoni G, Pea M, Reghellin D, et al. PEComas: the past, the present and the future. Virchows Arch 2008;452:119-132.
3. Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 2007;38:1361-1371. (Pubitemid 47247479)
4. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-151.
5. Eble JN. Angiomyolipoma of kidney. Semin Diagn Pathol 1998;15:21-40. (Pubitemid 28093786)
6. Cibas ES, Goss GA, Kulke MH, et al. Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol 2001;25:121-126. (Pubitemid 32001841)
7. Martignoni G, Pea M, Rigaud G, et al. Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions. Am J Surg Pathol 2000;24:889-894. (Pubitemid 30366279)
8. Eble JN, Amin MB, Young RH. Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component. Am J Surg Pathol 1997;21:1123-1130.
9. Martignoni G, Pea M, Bonetti F, et al. Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: a clinicopathologic and genetic study. Am J Surg Pathol 1998;22: 663-672. (Pubitemid 28280268)
10. Pea M, Bonetti F, Martignoni G, et al. Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol 1998;22:180-187. (Pubitemid 28113378)
11. Aydin H, Magi-Galluzzi C, Lane BR, et al. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 2009; 33:289-297.
12. Brimo F, Robinson B, Guo C, et al. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol 2010;34:715-722.
13. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011;35:161-176.
14. Martignoni G, Bonetti F, Pea M, et al. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome. Am J Surg Pathol 2002;26:198-205. (Pubitemid 34127499)
15. Pan CC, Chung MY, Ng KF, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol 2008;214:387-393.
16. Martignoni G, Pea M, Bonetti F, et al. Oncocytoma-like angiomyolipoma. A clinicopathologic and immunohistochemical study of 2 cases. Arch Pathol Lab Med 2002;126:610-612. (Pubitemid 34477961)
17. Fine SW, Reuter VE, Epstein JI, et al. Angiomyolipoma with epithelial cysts (AMLEC): a distinct cystic variant of angiomyolipoma. Am J Surg Pathol 2006;30: 593-599. (Pubitemid 44265011)
18. Davis CJ, Barton JH, Sesterhenn IA. Cystic angiomyolipoma of the kidney: a clinicopathologic description of 11 cases. Mod Pathol 2006;19:669-674.
19. Armah HB, Yin M, Rao UN, et al. Angiomyolipoma with epithelial cysts (AMLEC): a rare but distinct variant of angiomyolipoma. Diagn Pathol 2007;2:11.
20. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000;31:1242-1248.
21. Motyckova G, Weilbaecher KN, Horstmann M, et al. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 2001;98:5798-5803. (Pubitemid 32435722)
22. Pea M, Bonetti F, Zamboni G, et al. Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991;23: 185-188.
23. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol 1998;22:595-602. (Pubitemid 28213747)
24. Zavala-Pompa A, Folpe AL, Jimenez RE, et al. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers. Am J Surg Pathol 2001; 25:65-70. (Pubitemid 32001834)
25. Kaiserling E, Krober S, Xiao JC, et al. Angiomyolipoma of the kidney. Immunoreactivity with HMB-45. Lightand electron-microscopic findings. Histopathology 1994;25:41-48. (Pubitemid 24246472)
26. Xiao Y, Junfeng H, Tianhong L, et al. Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity. J Clin Endocrinol Metab 2006;91:4520-4527. (Pubitemid 44833434)
27. Pedica F, Pecori S, Vergine M, et al. Cathepsin-k as a diagnostic marker in the identification of microgranulomas in Crohn's disease. Pathologica 2009;101:109-111.
28. Eble JN, Sauter G, Epstein JI, et al. WHO: Tumours of the Urinary System and Male Genital Organs., Vol. IARC Press: Lyon, 2004.
29. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 2009;22:1016-1022.
30. Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 2010;34:1395-1406.
31. Chilosi M, Pea M, Martignoni G, et al. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 2009;22:161-166.
32. Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science 2009;325:473-477.
33. Sardiello M, Ballabio A. Lysosomal enhancement: a CLEAR answer to cellular degradative needs. Cell Cycle 2009;8:4021-4022.
34. Jimenez RE, Eble JN, Reuter VE, et al. Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol 2001;14:157-163. (Pubitemid 32246818)
35. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008;358: 200-203.
36. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28:835-840.
37. Wolff N, Kabbani W, Bradley T, et al. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol 2010;28:e65-e68.
38. Kneissel M, Luong-Nguyen NH, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004;35:1144-1156. (Pubitemid 39487361)
39. Bundscherer A, Hafner C, Maisch T, et al. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008;19:547-553. (Pubitemid 351176119)
40. Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008;128:980-987. (Pubitemid 351374287)